Metabolic dysfunction in Emirati subjects in Abu Dhabi: Relationship to levels of soluble RAGEs.

Autor:	Abdulle A; Public Health Research Center, New York University Abu Dhabi, United Arab Emirates., Inman CK; Public Health Research Center, New York University Abu Dhabi, United Arab Emirates., Saleh A; Department of Medicine, Sheikh Khalifa Medical City, United Arab Emirates., Noshi M; Department of Medicine, Sheikh Khalifa Medical City, United Arab Emirates., Galani D; Public Health Research Center, New York University Abu Dhabi, United Arab Emirates., Abdelwareth L; Department of Pathology, Cleveland Clinic Abu Dhabi, United Arab Emirates., Alsafar H; Center for Biotechnology, Khalifa University of Science & Technology, Abu Dhabi, United Arab Emirates.; Department of Biomedical Engineering, Khalifa University of Science & Technology, Abu Dhabi, United Arab Emirates., Elfatih A; Department of Medicine, Sheikh Khalifa Medical City, United Arab Emirates., Al Shamsi H; Department of Medicine, Sheikh Khalifa Medical City, United Arab Emirates., Ali R; Public Health Research Center, New York University Abu Dhabi, United Arab Emirates., Li H; Department of Population Health, New York University School of Medicine, NY, USA., Ramasamy R; Department of Medicine, New York University School of Medicine, NY, USA., Schmidt AM; Department of Medicine, New York University School of Medicine, NY, USA., Benbarka MM; Department of Medicine, Sheikh Khalifa Medical City, United Arab Emirates., Hassan MH; Department of Medicine, Sheikh Khalifa Medical City, United Arab Emirates.
Jazyk:	angličtina
Zdroj:	Journal of clinical & translational endocrinology [J Clin Transl Endocrinol] 2019 Apr 23; Vol. 16, pp. 100192. Date of Electronic Publication: 2019 Apr 23 (Print Publication: 2019).
DOI:	10.1016/j.jcte.2019.100192
Abstrakt:	Background: The United Arab Emirates is experiencing increasing rates of type 2 diabetes (T2D) and its complications. As soluble levels of the receptor for advanced glycation end products, (sRAGE), and endogenous secretory RAGE (esRAGE), the latter an alternatively spliced form of AGER (the gene encoding RAGE), have been reported to be associated with T2D and its complications, we tested for potential relationships between these factors and T2D status in Emirati subjects. Methods: In a case-control study, we recruited Emirati subjects with T2D and controls from the Sheikh Khalifa Medical City in Abu Dhabi. Anthropomorphic characteristics, levels of plasma sRAGE and esRAGE, and routine chemistry variables were measured. Results: Two hundred and sixteen T2D subjects and 215 control subjects (mean age, 57.4 ± 12.1 vs. 50.7 ± 15.4 years; P  < 0.0001, respectively) were enrolled. Univariate analyses showed that levels of sRAGE were significantly lower in the T2D vs. control subjects (1033.9 ± 545.3 vs. 1169.2 ± 664.1 pg/ml, respectively; P  = 0.02). Multivariate analyses adjusting for age, sex, systolic blood pressure, pulse, body mass index, Waist/Hip circumference ratio, fasting blood glucose, HDL, LDL, insulin, triglycerides, Vitamin D and urea levels revealed that the difference in sRAGE levels between T2D and control subjects remained statistically-significant, P  = 0.03, but not after including estimated glomerular filtration rate in the model, P  = 0.14. There were no significant differences in levels of esRAGE. Levels of plasma insulin were significantly higher in the control vs. the T2D subjects (133.6 ± 149.9 vs. 107.6 ± 93.3 pg/L. respectively; P  = 0.01, after adjustment for age and sex). Conclusion/discussion: Levels of sRAGE, but not esRAGE, were associated with T2D status in Abu Dhabi, but not after correction for eGFR. Elevated levels of plasma insulin in both control and T2D subjects suggests the presence of metabolic dysfunction, even in subjects without diabetes.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu